Ixabepilone bulk supplier for pharma manufacturers

Ixabepilone 15 mg, 45mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 15 mg, 45mg

Reference Brands: Ixempra (USA)

Ixabepilone is a semisynthetic epothilone analog used in the treatment of locally advanced or metastatic breast cancer. It works by stabilizing microtubules and preventing cancer cell division. It is mainly used in patients who have progressed on anthracyclines and taxanes. It is administered as an intravenous infusion.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ixabepilone? List it or send an offer →

Product Description:

Ixabepilone is a semisynthetic analogue of epothilone B, a compound from soil bacteria that stabilises microtubules much as the taxanes do but binds at a different site and, crucially, is a poor substrate for the P-glycoprotein efflux pump. Tumours commonly become taxane-resistant by overexpressing that pump and simply exporting the drug. Ixabepilone is not exported, which is why it retains activity where paclitaxel and docetaxel have stopped working.

It is used for locally advanced or metastatic breast cancer after progression on an anthracycline and a taxane, alone or with capecitabine. Peripheral neuropathy is the principal dose-limiting toxicity, usually sensory and usually reversible on dose reduction. Neutropenia, fatigue and myalgia are common. The formulation contains polyoxyethylated castor oil, so premedication with an antihistamine is mandatory and severe hypersensitivity remains possible. It is contraindicated with capecitabine in significant hepatic impairment because of toxic death risk.

Sourcing notes. Originator product with limited geographic approval — it was never authorised in Europe — so registration status must be checked carefully. Supplied as a kit of powder plus a specific diluent, which must be quoted together. Cytotoxic handling; refrigerated storage.

How Ixabepilone is supplied today, and licensing ahead of patent expiry

Ixabepilone is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Ixabepilone, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Ixabepilone supply →

Back to Listing

Frequently Asked Questions

Ixabepilone is used for the treatment of metastatic or locally advanced breast cancer. It is typically given to patients whose cancer has progressed after previous therapies, including anthracyclines, taxanes, and capecitabine. It works by inhibiting cancer cell growth and promoting cell death.

Ixabepilone is made from a semisynthetic analogue of epothilone B, a natural product derived from the myxobacterium

The trade name is

Ixempra is manufactured by

The generic name is Ixabepilone.

The brand name is

It is manufactured in the United States and other regulated markets by Bristol-Myers Squibb, and licensed generic versions may be produced in India by approved pharmaceutical manufacturers.

Ixempra (Ixabepilone) is developed and sold by R-Pharm US (originally Bristol Myers Squibb). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.